Dr. Reddy's Q3 profit tumbles, hit by U.S. pricing pressure [Reuters]
Dr. Reddy's Laboratories Ltd (RDY)
US:NYSE Investor Relations:
drreddys.com/investors
Company Research
Source: Reuters
Dr. Reddy's Q3 profit tumbles, hit by U.S. pricing pressure | Reuters Reuters Staff 1 Min Read REUTERS - Indian generic drugmaker Dr. Reddy’s Laboratories Ltd posted a 38.5 percent slump in quarterly net profit as sales declined due to pricing pressure in the United States, its biggest market. Net profit was 3.03 billion rupees ($47.7 million) in the third quarter ended Dec. 31, compared with 4.92 billion rupees a year earlier, the company said. bit.ly/2BubKli That compares with an average estimate of 3.4 billion rupees from 13 analysts polled by Thomson Reuters I/B/E/S. ($1 = 63.4900 rupees) Reporting by Jessica Kuruthukulangara in Bengaluru; Editing by Edwina Gibbs All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays. Š 2018 Reuters. All Rights Reserved. Dr. Reddy's Q3 profit tumbles, hit by U.S. pricing pressure REUTERS - Indian generic drugmaker Dr. Reddy’s Laboratories Ltd posted a 38.5 percent slump in quarterly net profit a
Show less
Read more
Impact Snapshot
Event Time:
RDY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RDY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RDY alerts
High impacting Dr. Reddy's Laboratories Ltd news events
Weekly update
A roundup of the hottest topics
RDY
News
- Super Generics Market Size Will Reach USD 128.62 Billion to 2031 - Revealed InsightAce Latest Study [Yahoo! Finance]Yahoo! Finance
- Indian shares set to open lower on fading US rate cut hopes [Reuters]Reuters
- Dr. Reddy's Laboratories Limited (NYSE: RDY) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.MarketBeat
- Aurigene Pharmaceutical Services Ltd. introduces Aurigene.AI™, an artificial intelligence (AI) and machine learning (ML) assisted drug discovery platform [Yahoo! Finance]Yahoo! Finance
- Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates [Yahoo! Finance]Yahoo! Finance
RDY
Earnings
- 1/31/24 - Beat
RDY
Sec Filings
- 4/23/24 - Form 6-K
- 4/22/24 - Form 6-K
- 4/19/24 - Form 6-K
- RDY's page on the SEC website